Charter Medical’s cryopreservation containers are approved


Charter Medical, a division of Lydall, Inc., has announced that its 510(k) cleared CELL-FREEZE® cryogenic storage containers have been approved by Dana-Farber Cancer Institute in Boston, Massachusetts.

CELLFREEZE® was designed for peripherally derived stem cells and used for cryogenic temperature applications as low as -196˚c for storage, preservation, and transfer.

Dana-Farber Cancer Institute, a national leader in adult and pediatric cancer care and research, will be using CELLFREEZE® for stem cell applications.

Peter Ferris, President of Charter Medical commented, “We are pleased Dana-Farber Cancer Institute, a world class cancer research centre, selected CELL-FREEZE® for stem cell clinical applications. We are encouraged by market acceptance of CELL-FREEZE® and currently have our product being evaluated at over 30 stem cell research centres across North America.”

... to continue reading you must be subscribed

Subscribe Today

Paywall Asset Header Graphic

To access hundreds of features, subscribe today! At a time when the world is forced to go digital more than ever before just to stay connected, discover the in-depth content our subscribers receive every month by subscribing to gasworld.

Please wait...